Quarterly ResultAug 11, 2026, 07:04 PM
Anteris Q2 2026: Medicare Reimbursement, US Trial Recruitment
AI Summary
Anteris Technologies Global Corp. reported Q2 2026 financial results and provided a corporate update, highlighting significant progress for its DurAVR® THV. The company secured U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial and initiated U.S. patient recruitment in May 2026, expanding active recruitment across key geographies. Financially, Anteris reported net operating cash outflows of $20.8 million and R&D expenses of $23.4 million for the quarter, primarily supporting the PARADIGM Trial and manufacturing scale-up.
Key Highlights
- Secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial.
- Initiated U.S. recruitment in the PARADIGM Trial, with first patients enrolled in May 2026.
- Expanded PARADIGM Trial recruitment in U.S., Denmark, and the Netherlands.
- Appointed Ms. Susan Knight and Mr. Stephen Denaro to the Board of Directors.
- Net operating cash outflows for Q2 2026 were $20.8 million.
- R&D expenses for Q2 2026 were $23.4 million, driven by trial and manufacturing.
Price Impact
More from AVR